Mr. Geno Germano has been the Chairman of the company since 2024. Previously, he served on the board of directors of the company. He also serves as the President and Chief Executive Officer at Elucida Oncology. He has experience in the pharmaceutical industry and held leadership roles at Intrexon, Pfizer, Wyeth, and Johnson & Johnson.

Mr. Barry Greene has been the Chief Executive Officer and Director of the company since 2020. Prior to this role, he served as President of Alnylam Pharmaceuticals Inc from 2007 to September 2020, and as its Chief Operating Officer from 2003 to 2016.

Ms. Kimi Iguchi has been the Chief Financial Officer and Treasurer of the company since 2013. Prior to this, she served as the Chief Operating Officer, North America, for Santhera Pharmaceuticals. Ms. Iguchi also served as the Vice President of Finance at Cyberkinetics Neurotechnology Systems, Senior Director of Financial Reporting and Analysis at Millennium Pharmaceuticals and the Senior Manager of External Reporting at Biogen Inc. She also worked as a business assurance manager at PricewaterhouseCoopers LLP and started her career in chemistry-related positions at various Boston-based companies.

Mr. Laura Gault, MD, Ph.D has been the Chief Medical Officer of the company since November 2022. Prior to this. he served as the Vice President, Therapeutic Area Head for Neurology and Ophthalmology at Alexion/Astra Zeneca Rare Disease. Previously, he served as the Vice President, Neurology Clinic Development at Vertex Pharmaceuticals and Group Project Leader at AbbVie.

Dr. Albert J. Robichaud has been the Chief Scientific Officer of the company since 2011. Prior to this, he served as the Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck Inc. From 2002 to 2010, Dr. Robichaud served as a Senior Director and Head of Neuroscience Discovery Chemistry department of Wyeth Research.